A Phase 3 interventional study of CHF6001 1600µg and CHF6001 3200µg in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Terminated at 460 sites in 28 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Bronchitis, Chronic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Bronchitis, Chronic · United States.
Among the 100 studies in Bronchitis, Chronic with a site in United States, this one is the 3rd largest by enrollment of the 82 interventional ones that give a count, is one of 3 that started in 2021, is one of 19 in phase 3, and was the 89th registered.
209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.
Browse Bronchitis, Chronic studies →7 of the 100 studies in Bronchitis, Chronic with a site in United States are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Austria and 15 more countries
Ages 40–75
UCB Biopharma SRL · Sites in United States, China
Ages 40–80
Rush University Medical Center · Sites in United States
Ages 40+
Freenome Holdings Inc. · Sites in United States
Ages 50+
COPD Foundation · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 25 · Phase 3 19 · Phase 4 15
First in 1994; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,973 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.
Median enrollment 126 across the 82 interventional studies, 1,429 across the 18 observational. Of the 78 that completed or were terminated, 33 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 100 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
Chiesi Farmaceutici S.p.A. has 2 studies filed under Bronchitis, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Bronchitis, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06981078Upstream Bio Inc.A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 100 studies in Bronchitis, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.
This study's enrollment of 3,973 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.
Browse Bronchitis, Chronic studies →Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
Compared within Bronchitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pulmonary Disease, Chronic Obstructive. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CHF6001 1600µg
Drug: CHF6001 3200µg
Drug: Placebo
Drug: Roflumilast
CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
\- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
The number of moderate and severe exacerbations occurring during the planned 52-week treatment period.
Moderate or severe exacerbation is defined by symptomatic worsening of COPD: * Moderate : requiring use of systemic corticosteroids (oral/IV/IM corticosteroids), and/or use of antibiotics * Severe : requiring hospitalisation or resulting in death
Time frame: Up to 52 weeks
The time to first moderate or severe exacerbation.
The time to first moderate or severe exacerbation.
Time frame: Up to 52 weeks
The annual rate of severe exacerbations.
The annual rate of severe exacerbations.
Time frame: Up to 52 weeks
The time to first severe exacerbation.
The time to first severe exacerbation.
Time frame: Up to 52 weeks
The number of all on-treatment severe exacerbations.
The number of all on-treatment severe exacerbations.
Time frame: Up to 52 weeks
The number of all on-treatment exacerbations requiring systemic corticosteroids.
The number of all on-treatment exacerbations requiring systemic corticosteroids.
Time frame: Up to 52 weeks
Change from baseline (pre-dose Visit 2) in pre-dose FEV1, at week 52.
Change from baseline (pre-dose Visit 2) in pre-dose FEV1, at week 52.
Time frame: At week 52
Change from baseline in Saint Georges Respiratory Questionnaire (SGRQ) total and domain scores at week 52.
Change from baseline in Saint Georges Respiratory Questionnaire (SGRQ) total and domain scores at week 52.
Time frame: At week 52
Saint Georges Respiratory Questionnaire response (SGRQ) (change from baseline SGRQ total score ≤ -4) at week 52.
Saint Georges Respiratory Questionnaire response (SGRQ) (change from baseline SGRQ total score ≤ -4) at week 52.
Time frame: At week 52
Change from baseline to last inter-visit period (week 40-52) in EXACT-Respiratory Symptoms (E-RS) Total and subscale scores.
Change from baseline to last inter-visit period (week 40-52) in EXACT-Respiratory Symptoms (E-RS) Total and subscale scores.
Time frame: Up to 52 weeks
E-RS response (change from baseline E-RS Total score ≤ -2) at week 52.
E-RS response (change from baseline E-RS Total score ≤ -2) at week 52.
Time frame: At week 52
Change from baseline to last inter-visit period (week 40-52) in the percentage of days without intake of rescue medication and in the average rescue medication use (number of puffs).
Change from baseline to last inter-visit period (week 40-52) in the percentage of days
Time frame: Up to 52 weeks
Time to study medication discontinuation for any reason.
Time to study medication discontinuation for any reason.
Time frame: Up to 52 weeks
Time to moderate or severe exacerbation or study medication discontinuation due to any adverse event, lack of efficacy or death (composite endpoint) and time to study medication discontinuation component.
Time to moderate or severe exacerbation or study medication discontinuation due to any adverse event, lack of efficacy or death (composite endpoint) and time to study medication discontinuation component.
Time frame: Up to 52 weeks
Time to first moderate/severe exacerbation or study medication discontinuation due to any class-related AE, lack of efficacy, or death (composite endpoint) and time to study medication discontinuation component.
Time to first moderate/severe exacerbation or study medication discontinuation due to any class-related AE, lack of efficacy, or death (composite endpoint) and time to study medication discontinuation component.
Time frame: Up to 52 weeks
Key Secondary Variable: Change from baseline in SGRQ Total score at week 52
Key Secondary Variable: Change from baseline in SGRQ Total score at week 52
Time frame: At week 52
Showing the first 100 of 460 sites across 28 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Dec 2025, 53 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tanimilast